Hasan Mohammad Nazmul, Wang Huaiwen, Luo Wenyi, Du Yanhong, Li Tiangang
Harold Hamm Diabetes Center, Department of Biochemistry and Physiology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States.
Laboratory for Molecular Biology and Cytometry Research, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States.
Am J Physiol Gastrointest Liver Physiol. 2025 Jul 1;329(1):G45-G57. doi: 10.1152/ajpgi.00044.2025. Epub 2025 May 26.
Cholestasis results from impaired bile flow that causes accumulation of hepatic bile acid and injury. Alleviating bile acid hepatobiliary toxicity is a major therapeutic goal in cholestasis. Our recent study revealed a potent anticholestasis effect of glycine-conjugated β-muricholic acid (Gly-βMCA) in knockout (KO) mice with humanized hydrophobic bile acid composition. To better understand the mechanisms and human relevance of the therapeutic benefits of Gly-βMCA, we investigated the effects of Gly-βMCA on bile acid metabolism and biliary injury in KO mice, a cholestasis model with a hydrophilic murine bile acid composition. Gly-βMCA significantly reduced serum alkaline phosphatase (ALP), ductular reaction, and liver cytokine expression in female mice but offered little benefits in male mice. Consistently, Gly-βMCA reduced hepatic bile acids and total bile acid pool size in female but not male mice, due to its ability to promote fecal bile acid excretion. However, the endogenous taurine-conjugated muricholic acid (T-MCA) limited the ability of Gly-βMCA to further enrich the bile acid pool with Gly-βMCA-derived T-βMCA to reduce bile acid hydrophobicity. Overall, Gly-βMCA showed diminished therapeutic efficacy in KO mice than KO mice, which may be due to differences in bile acid hydrophobicity and disease etiology in the two cholestasis models. These findings suggest that the benefits of Gly-βMCA are mediated by its unique pharmacokinetics, which allows for simultaneous reduction of bile acid pool size and hydrophobicity. Gly-βMCA may be a promising therapy for treating human cholestasis, despite its reduced efficacy in improving the toxicity profile of murine bile acid pool. Gly-βMCA decreases liver injury in female but not male KO mice. Gly-βMCA blocks bile acid absorption to reduce bile acid pool in female KO mice. Gly-βMCA reduces bile acid hydrophobicity by causing T-βMCA enrichment in bile, but this therapeutic benefit was partially masked by a murine bile acid composition due to abundantly synthesized T-MCA in KO mice. Gly-βMCA alleviates bile acid hepatobiliary toxicity by reducing both bile acid pool size and hydrophobicity.
胆汁淤积是由胆汁流动受损导致肝胆汁酸积聚和损伤引起的。减轻胆汁酸的肝胆毒性是胆汁淤积治疗的主要目标。我们最近的研究揭示了甘氨酸结合型β-鼠胆酸(Gly-βMCA)在具有人源化疏水胆汁酸组成的基因敲除(KO)小鼠中具有强大的抗胆汁淤积作用。为了更好地理解Gly-βMCA治疗益处的机制及其与人类的相关性,我们研究了Gly-βMCA对具有亲水性鼠胆汁酸组成的KO小鼠胆汁酸代谢和胆管损伤的影响。Gly-βMCA显著降低了雌性小鼠的血清碱性磷酸酶(ALP)、小胆管反应和肝脏细胞因子表达,但对雄性小鼠益处不大。一致的是,由于Gly-βMCA促进粪便胆汁酸排泄的能力,它减少了雌性而非雄性小鼠的肝脏胆汁酸和总胆汁酸池大小。然而,内源性牛磺酸结合型鼠胆酸(T-MCA)限制了Gly-βMCA通过Gly-βMCA衍生的T-βMCA进一步丰富胆汁酸池以降低胆汁酸疏水性的能力。总体而言,Gly-βMCA在KO小鼠中的治疗效果比在KO小鼠中减弱,这可能是由于两种胆汁淤积模型中胆汁酸疏水性和疾病病因的差异。这些发现表明,Gly-βMCA的益处是由其独特的药代动力学介导 的,这使得它能够同时降低胆汁酸池大小和疏水性。尽管Gly-βMCA在改善鼠胆汁酸池毒性方面的功效降低,但它可能是治疗人类胆汁淤积的一种有前途的疗法。Gly-βMCA可减轻雌性而非雄性KO小鼠的肝损伤。Gly-βMCA通过阻止胆汁酸吸收来减少雌性KO小鼠的胆汁酸池。Gly-βMCA通过导致胆汁中T-βMCA富集来降低胆汁酸疏水性,但由于KO小鼠中大量合成的T-MCA,这种治疗益处被鼠胆汁酸组成部分掩盖。Gly-βMCA通过降低胆汁酸池大小和疏水性来减轻胆汁酸的肝胆毒性。